{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:20Z","timestamp":1786120280198,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Morvan syndrome is a rare and complex autoimmune disorder affecting multiple sites of neuraxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report:<\/jats:title>\n                    <jats:p>We present fulminant Morvan syndrome, developing on a background of chronic myasthenia gravis. A 54-year-old gentleman presented with fluctuating ophthalmoplegia and proximal muscles weakness of 7 years duration that remitted with pyridostigmine and prednisolone. He developed insomnia of 2 months duration, worsening of myasthenic symptoms and respiratory distress, dysautonomia, encephalopathy, and peripheral nerve hyperexcitability. Antibodies against contactin-associated protein (CASPR) 2 were detected in serum. Computed tomography of thorax showed a thymic mass. He received intravenous methyl prednisolone and plasmapheresis. Antibodies against CASPR and thymic lesion reduced with immunotherapy. However, he developed persistent hypotension and expired after 11 weeks of hospital stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Clinical clues for diagnosis of Morvan syndrome and therapeutic changes faced by the treating team are highlighted in this report. Increased awareness and prompt testing for CASPR2 antibody is warranted so that early immunotherapy can be initiated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/nrl.0000000000000097","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T20:36:15Z","timestamp":1482611775000},"page":"29-33","source":"Crossref","is-referenced-by-count":15,"title":["Fatal Morvan Syndrome Associated With Myasthenia Gravis"],"prefix":"10.1097","volume":"22","author":[{"given":"Madhu","family":"Nagappa","sequence":"first","affiliation":[{"name":"Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mahadevan","sequence":"additional","affiliation":[{"name":"Neuropathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjib","family":"Sinha","sequence":"additional","affiliation":[{"name":"Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parayil S.","family":"Bindu","sequence":"additional","affiliation":[{"name":"Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavagada S.","family":"Mathuranath","sequence":"additional","affiliation":[{"name":"Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheminikara","family":"Bineesh","sequence":"additional","affiliation":[{"name":"Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose D.","family":"Bharath","sequence":"additional","affiliation":[{"name":"Neuro-Imaging and Interventional Radiology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun B.","family":"Taly","sequence":"additional","affiliation":[{"name":"Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230929","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan\u2019s syndrome and acquired neuromyotonia","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"R2-20230929","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ana.23577","article-title":"Morvan syndrome: clinical and serological observations in 29 cases","volume":"72","author":"Irani","year":"2012","journal-title":"Ann Neurol"},{"key":"R3-20230929","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/jnnp.2003.031401","article-title":"Sub-acute presentation of Morvan\u2019s syndrome after thymectomy","volume":"75","author":"Cottrell","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R4-20230929","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2011.08.024","article-title":"Morvan\u2019s syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex","volume":"312","author":"Loukaides","year":"2012","journal-title":"J Neurol Sci"},{"key":"R5-20230929","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/brain\/124.12.2417","article-title":"Morvan\u2019s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels","volume":"124","author":"Liguori","year":"2001","journal-title":"Brain"},{"key":"R6-20230929","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.22297","article-title":"Investigations of CASPR2, an autoantigen of encephalitis and neuromyotonia","volume":"69","author":"Lancaster","year":"2011","journal-title":"Ann Neurol"},{"key":"R7-20230929","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/mus.23311","article-title":"Rituximab therapy for morvan syndrome associated with myasthenia gravis","volume":"46","author":"Weiss","year":"2012","journal-title":"Muscle Nerve"},{"key":"R8-20230929","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11910-013-0341-8","article-title":"Agrypnia excitata","volume":"4","author":"Provini","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"suppl 2","key":"R9-20230929","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.sleep.2011.10.004","article-title":"Agrypnia excitata","volume":"12","author":"Lugaresi","year":"2011","journal-title":"Sleep Med"},{"key":"R10-20230929","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.sleep.2011.05.005","article-title":"Morvan chorea and agrypnia excitata: when video-polysomnographic recording guides the diagnosis","volume":"12","author":"Provini","year":"2011","journal-title":"Sleep Med"},{"key":"R11-20230929","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamaneurol.2013.592","article-title":"Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping","volume":"70","author":"Klein","year":"2013","journal-title":"JAMA Neurol"},{"key":"R12-20230929","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1212\/01.WNL.0000122648.19196.02","article-title":"Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody","volume":"13","author":"Thieben","year":"2004","journal-title":"Neurology"},{"key":"R13-20230929","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/jnnp.65.6.857","article-title":"Morvan\u2019s fibrillary chorea: a paraneoplastic manifestation of thymoma","volume":"65","author":"Lee","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R14-20230929","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ncl.2010.03.024","article-title":"Management of voltage-gated potassium channel antibody disorders","volume":"28","author":"Merchut","year":"2010","journal-title":"Neurol Clin"},{"key":"R15-20230929","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1097\/JTO.0b013e3181f23f04","article-title":"Caspr2 antibodies in patients with thymomas","volume":"5","author":"Vincent","year":"2010","journal-title":"JThorac Oncol"},{"key":"R16-20230929","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF01735061","article-title":"Concurrence of myasthenia gravis and chor\u00e9e fibrillaire de Morvan","volume":"239","author":"Iwasaki","year":"1990","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"R17-20230929","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/brain\/awh077","article-title":"Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis","volume":"127","author":"Vincent","year":"2004","journal-title":"Brain"},{"key":"R18-20230929","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"R19-20230929","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1212\/01.WNL.0000032502.89361.0C","article-title":"Thymoma in patients with MG: characteristics and long-term outcome","volume":"59","author":"Evoli","year":"2002","journal-title":"Neurology"},{"issue":"suppl 2","key":"R20-20230929","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1097\/JTO.0000000000000300","article-title":"Paraneoplastic disorders in thymoma patients","volume":"9","author":"Evoli","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R21-20230929","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1212\/01.wnl.0000336972.62597.41","article-title":"Immunotherapy-reversed compulsive, monoaminergic, circadian rhythm disorder in morvan syndrome","volume":"71","author":"Spinazzi","year":"2008","journal-title":"Neurology"},{"key":"R22-20230929","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/cncr.21875","article-title":"Preoperative steroid pulse therapy for invasive thymoma: clinical experience and mechanism of action","volume":"106","author":"Kobayashi","year":"2006","journal-title":"Cancer"}],"container-title":["The Neurologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00127893-201701000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:26:07Z","timestamp":1786047967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00127893-201701000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/nrl.0000000000000097","relation":{},"ISSN":["1074-7931"],"issn-type":[{"value":"1074-7931","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}